-The Business Standard Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker. This is because the judgement...

-The Hindu   It joins hands with AIIMS to offer health services to villagers Raipur: Maoists as well as security forces have hit upon new strategies to gain an upper hand in the ongoing conflict. The latest one - to check the influence of rebels - has come from the Central Reserve Police Force (CRPF). It is not at all a military manoeuvre, but an offer of medical assistance to villagers in the Maoist-controlled...

-The Hindu Considering the knowledge of English as a mark of social advancement and that of the vernacular as backwardness disenfranchises significant sections of society In a village in Ghazipur district that borders Varanasi, there is a young man who teaches English and "personality development" to the sons and daughters of local shopkeepers, farmers and truck drivers. The classes are held from 6 to 8 in the morning and again in the...

-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...